Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: A randomized, 24-week, open-label, active-controlled trial - Ito, D; Shimizu, S; Inoue, K (Diabetes Care, 2017)
et al.